8-K filing — MBX Biosciences, Inc. (MBX)
Filed: 2026-08-27 AccNo: 0001193125-26-369674 Size: 235 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating Once-Weekly Canvuparatide For Treatment Of Chronic Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year clinical benefitGlobal registrational trial to enroll approximately 160 adults with HP to support
JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.
Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $88.